Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial.
Clinical Added Value
|no clinical added value||
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication.
Évaluation des médicaments